# US 12,178,900 B2 · Pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,900 B2
- Document ID: US12178900B2
- Status: Granted
- Kind: B2
- Application number: 17/523,661
- Filed: 2021-11-10
- Published: 2022-04-21
- Granted: 2024-12-31
- Earliest claimed: 2017-03-24
- Assignees: Joyderma AG
- Applicants: Joyderma AG
- Inventors: Teo Albarano
- Web page: https://patentgrep.com/patent/US12178900B2

## CPC

- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K 8/11: Encapsulated compositions
- A61K 8/14: Liposomes; Vesicles
- A61K 8/347: {Phenols}
- A61K 8/63: Steroids; Derivatives thereof
- A61K 8/67: Vitamins
- A61K 8/671: {Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal}
- A61K 8/673: {Vitamin B group}
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 8/678: {Tocopherol, i.e. vitamin E}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/728: Hyaluronic acid
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 17/06: Antipsoriatics
- A61Q 17/04: Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
- A61Q 19/007: {Preparations for dry skin}
- H04W 36/0058: {Transmission of hand-off measurement information, e.g. measurement reports}
- A61K 2800/5922: At least two compounds being classified in the same subclass of A61K8/18
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- H04W: WIRELESS COMMUNICATION NETWORKS (broadcast communication H04H; communication systems using wireless links for non-selective communication, e.g. wireless extensions H04M1/72)

## Abstract

A composition including a synergistic combination of a vitamin D3 or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.

## Claims

### Claim 1

A method for preparing a homogeneous, stable liposomal hydrogel comprising the steps of:
a) dispersing dried phospholipids at room temperature in a first aqueous solution to obtain phospholipid colloids;
b) dispersing separately hyaluronic acid at room temperature in a second aqueous solution, wherein the hyaluronic acid is a mixture of low molecular, medium molecular, and high molecular weight hyaluronic acid;
c) liquifying 7-dehydrocholesterol (7-DHC) at a temperature between 14° and 150° C.;
d) adding an organic solvent to the liquified 7-DHC obtained in step c) to obtain a mixture;
e) admixing the mixture obtained in step d) to the phospholipid colloids obtained in step a) under stirring at room temperature to obtain colloidal spheres of 20-150 nm;
f) adding the dispersed hyaluronic acid obtained in step b) to the colloidal spheres of step e) to obtain a further mixture; and
g) continue stirring the further mixture at room temperature to obtain a homogeneous, stable liposomal hydrogel comprising the 7-DHC and the mixture of hyaluronic acids encapsulated in phospholipid colloids.

### Claim 2 (depends on 1)

The method according to claim 1, wherein 7-DHC is present at a concentration of 0.01 to 0.5 wt %.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the mixture of hyaluronic acid is present at a concentration of 0.01 to 8 wt %.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the organic solvent is propylene glycol.

### Claim 5 (depends on 1)

The method according to claim 1 wherein in step (g) stirring is carried out for 20 minutes.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the homogeneous, stable liposomal hydrogel further comprises one or more further components selected from a vitamin A added at step d), at least one vitamin B added at step b), a vitamin C added at step b), and a vitamin E added at step d).

### Claim 7 (depends on 6)

The method according to claim 6 wherein the homogeneous, stable liposomal hydrogel further comprises the at least one vitamin B added at step b), selected from riboflavin (vitamin B2), niacinamide (vitamin B3), dexpanthenol (Provitamin B5), and/or folic acid (vitamin B9).

### Claim 8 (depends on 1)

The method according to claim 1 wherein the homogeneous, stable liposomal hydrogel further comprises i) retinyl palmitate (vitamin A), (ii) riboflavin (vitamin B2), (iii) niacinamide (vitamin B3), (iv) dexpanthenol (Provitamin B5), (v) folic acid (vitamin B9), (vi) L-ascorbic acid (vitamin C) and (vii) tocopheryl acetate (vitamin E), added at step d).

### Claim 9 (depends on 1)

The method according to claim 1 wherein the homogeneous, stable liposomal hydrogel further comprises at least one UV-filter added at step b) or step d).

### Claim 10 (depends on 1)

The method according to claim 1 wherein the homogeneous, stable liposomal hydrogel further comprises at least one adjuvant selected from the group consisting of surfactants, emulsifying agents, emollients, thickening agents, conditioning conservants, buffering agents, humectants, and perfuming agents, each added at step b) or step d).

### Claim 11 (depends on 10)

The method according to claim 10 wherein the homogeneous, stable liposomal hydrogel further comprises the surfactant added at step b) or step d), selected from a polysorbate, a polycarbonate, polyvinylpyrrolidon (PVP), polyvidon, ovidonmembranes, povidone, copovidone, hypromellose or Eudragit EPO.

### Claim 12 (depends on 1)

A liposomal hydrogel obtained according to a method of claim 1.

### Claim 13 (depends on 12)

The liposomal hydrogel according to claim 12 further comprising one or more further components selected from a vitamin A, at least one vitamin B, a vitamin C, and a vitamin E.

### Claim 14 (depends on 13)

The liposomal hydrogel according to claim 13 including the at least one vitamin B, wherein the at least one vitamin B is riboflavin (vitamin B2), niacinamide (vitamin B), dexpanthenol (Provitamin B5), and/or folic acid (vitamin B9).

### Claim 15 (depends on 12)

The liposomal hydrogel according to claim 12 further comprising i) retinyl palmitate (vitamin A), (ii) riboflavin (vitamin B2), (iii) niacinamide (vitamin B3), (iv) dexpanthenol (Provitamin B5), (v) folic acid (vitamin B9), (vi) L-ascorbic acid (vitamin C) and (vii) tocopheryl acetate (vitamin E).

### Claim 16 (depends on 12)

The liposomal hydrogel according to claim 12 further comprising at least one UV-filter.

### Claim 17 (depends on 12)

The liposomal hydrogel according to claim 12 further comprising at least one adjuvant selected from the group consisting of surfactants, emulsifying agents, emollients, thickening agents, conditioning conservants, buffering agents, humectants, and perfuming agents.

### Claim 18 (depends on 17)

The liposomal hydrogel according to claim 17 including the surfactant, wherein the surfactant is a polysorbate, polycarbonate, polyvinylpyrrolidon (PVP), polyvidon, ovidonmembranes, povidone, copovidone, hypromellose or Eudragit EPO.

### Claim 19 (depends on 1)

The method according to claim 1 further comprising adding to the liquified at least one vitamin D3 or derivative thereof obtained in step c) a lipophilic agent selected from a vitamin A or a vitamin E.

### Claim 20 (depends on 1)

The method according to claim 1 further comprising dispersing with the hyaluronic acid in the second aqueous solution a hydrophilic agent selected from a vitamin B or a vitamin C.